References

Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial

10.1067/mhj.2001.117600 · 2001 · External reference

Influence of global region on outcomes in large heart failure β-Blocker trials

10.1016/j.jacc.2011.03.057 · 2011 · External reference

International differences in treatment effect: do they really exist and why?

10.1093/eurheartj/eht071 · 2013 · External reference

Ethical and scientific implications of the globalization of clinical research

10.1056/nejmsb0803929 · 2009 · External reference

Race, genetic variation, and therapeutic response disparities in heart failure

2014 · External reference

How race becomes biology: embodiment of social inequality

10.1002/ajpa.20983 · 2009 · External reference

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

10.1016/j.ahj.2011.09.007 · 2011 · External reference

Spironolactone for heart failure with preserved ejection fraction

10.1056/nejmoa1313731 · 2014 · External reference

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial

10.1016/s0140-6736(03)14285-7 · 2003 · External reference

Irbesartan in patients with heart failure and preserved ejection fraction

10.1056/nejmoa0805450 · 2008 · External reference

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial

10.1161/circulationaha.114.013255 · 2015 · External reference

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

10.1016/j.jacc.2008.07.056 · 2008 · External reference

The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction

10.1093/eurjhf/hfp003 · 2009 · External reference

Relative importance of history of heart failure hospitalization and N-terminal pro-B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction

2015 · External reference

International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction

10.1161/circulationaha.114.012284 · 2015 · External reference

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

10.1001/jama.2013.905 · 2013 · External reference

Defining diastolic heart failure and identifying effective therapies

10.1001/jama.2013.1569 · 2013 · External reference

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial

10.1161/circheartfailure.111.962654 · 2011 · External reference

Increasing the sample size when the unblinded interim result is promising

10.1002/sim.1688 · 2004 · External reference

Adaptive increase in sample size when interim results are promising: a practical guide with examples

10.1002/sim.4102 · 2011 · External reference

Unresolved reference

External reference